Founders who reach platform-scale success face a structural problem: the company they built can no longer execute the science they want to do. Şahin and Türeci's planned 2026 spin into a new mRNA company is the engineered answer — separate frontier research from commercial discipline, retain agency, keep economic exposure through BioNTech's planned minority stake. It is the rarest move in European deep tech because it requires founders who own the cap table to design it. Intr